RESEARCH TRIANGLE PARK, N.C., June 12, 2009 (GLOBE NEWSWIRE) -- Icagen, Inc. (Nasdaq:ICGN) today reported the completion of enrollment in the Company’s Phase II proof-of-concept study of senicapoc in patients with exercise induced asthma. Initial results from this study are expected during the second half of this year.
